ANTIBODIES

Our portfolio offers a broad range of high-quality, specialized antibodies designed to support research and diagnostics in neurodegenerative diseases. They enable reliable measurement of key biomarkers – from amyloid and tau to synaptic markers, neurofilament light (NfL) and beyond – in both cerebrospinal fluid (CSF) and blood samples.

These antibodies are available exclusively to our partners and collaborators, including technology providers and pharmaceutical companies. If you are interested in evaluating one of our antibodies onto your own technology platform, please contact us to request a test sample or to learn more about how we can support your work. Discover our portfolio below.

Amyloid

Amyloid-beta is a useful biomarker for the detection of the Alzheimer pathology, even in an early stage. Decreased amyloid-beta 42/40 ratio in CSF and plasma correlates highly with the presence of amyloid plaques in Alzheimer brains.

ADx101

Mouse monoclonal antibody against B Amyloid 1-x

Amyloid 1-x specific

ADx102

Mouse monoclonal antibody against human β Amyloid x-42

Amyloid x-42 specific

ADx103

Mouse monoclonal antibody against human β Amyloid x-40

Amyloid x-40 specific

ADx401

Mouse monoclonal antibody against human BACE-1

BACE-1 specific

ADx402

Mouse monoclonal antibody against human BACE-1

BACE-1 specific

(p-)Tau

Total tau and P-tau are good indicators of neuronal damage. P-tau specifically measures damage caused by Alzheimer’s disease. In contrast, total tau is a general marker, which can also be used to determine severe concussion.

Available anti Tau antibodies

ADx201

Mouse monoclonal antibody against human total tau

Proline rich domain

ADx202

Mouse monoclonal antibody against human total tau

Proline rich domain

ADx204

Mouse monoclonal antibody against human total tau

N-terminal tau

ADx215

Mouse monoclonal antibody against human total tau

N-terminal tau

ADx216

Mouse monoclonal antibody against human total tau

C-terminal tau

ADx217

Mouse monoclonal antibody against human total tau (CSF use only)

N-terminal Tau

ADx218

Recombinant mouse monoclonal antibody against human total tau

N-terminal Tau

Available anti p-Tau antibodies

ADx252

Rabbit monoclonal antibody against human P-tau181

Phosphorylated Threonine 181 specific

ADx253

Mouse monoclonal antibody against human P-tau231

Phosphorylated Threonine 231 specific

ADx254

Mouse monoclonal antibody (Fab) fragment against human P-tau217 (CSF use only)

Phosphorylated Threonine 217 specific

ADx257

Recombinant mouse monoclonal antibody against human P-tau231

Phosphorylated Threonine 231 specific

ADx258

Mouse monoclonal antibody against human P-tau217

Phosphorylated Threonine 217 specific

Synaptic markers

Neurons are interconnected by multiple synapses. In Alzheimer’s disease, synapses show gradual degeneration. Neurogranin and Neuronal Pentraxin 2 (NPTX2) in CSF are good biomarkers for synapse integrity. They will help predict the progression of the disease.

ADx403

Mouse monoclonal antibody against human neurogranin

N-terminal

ADx451

Mouse monoclonal antibody against human truncated neurogranin

Specific for C-terminal truncation at P75

ADx409

Mouse monoclonal antibody against human NPTX-2

ADx410

Mouse monoclonal antibody against human NPTX-2

Synuclein

The concentration of α-synuclein in CSF is linked to the presence of Lewy bodies in the brain, which are typically found in the brains of Parkinson’s disease patients. Other α-synuclein forms are in development.

ADx301

Rabbit monoclonal antibody against human α-synuclein

Neurofilament Light chain

Neurofilament light chain (Nf-L) is a valuable biomarker for neurodegeneration, including in Alzheimer’s disease. Elevated levels of Nf-L in cerebrospinal fluid (CSF) and plasma reflect axonal damage and correlate with disease progression and cognitive decline.

ADx206

Mouse monoclonal antibody against human Nf-L

ADx209

Mouse monoclonal antibody against human Nf-L

Soluble TREM-2

Soluble TREM-2 (sTREM-2) is another promising biomarker linked to microglial activation. Increased levels of sTREM-2 in CSF are associated with neuroinflammatory responses and appear to peak during early symptomatic stages of Alzheimer’s pathology, providing insight into the immune response in the diseased brain.

ADx601

Rabbit monoclonal antibody against human sTREM-2

ADx602

Rabbit monoclonal antibody against human sTREM-2

Contact us for more information.